Patents by Inventor Pu Xia
Pu Xia has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20080279897Abstract: The present invention relates generally to a method of modulating hyperglycaemia-induced endothelial cell functioning and agents useful for same. More particularly, the present invention relates to a method of modulating hyperglycaemia-induced vascular endothelial cell functioning by modulating intracellular sphingosine kinase-mediated signalling. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of the adverse vascular endothelial cell functioning associated with conditions characterised by hyperglycaemia, and/or diabetes mellitus, per se.Type: ApplicationFiled: January 17, 2006Publication date: November 13, 2008Applicant: MEDVET SCIENCE PTY. LTD.Inventors: Pu Xia, Lijun Wang, Mathew Alexander Vadas
-
Publication number: 20080279841Abstract: The present invention relates generally to a sphingosine kinase variant and to derivatives, analogues, chemical equivalents and mimetics thereof exhibiting reduced catalytic activity and, more particularly, to sphingosine kinase variants which exhibit a reduced capacity to phosphorylate sphingosine to sphingosine-1-phosphate. The present invention also contemplates genetic sequences encoding said sphingosine kinase variants and derivatives, analogues and mimetics thereof. The variants of the present invention are useful in a range of therapeutic and prophylactic applications.Type: ApplicationFiled: June 20, 2001Publication date: November 13, 2008Applicant: MEDVET SCIENCE PTY LTD.Inventors: Stuart Pitson, Paul Moretti, Julia Zebol, Pu Xia, Jennifer Gamble, Mathew Vadas, Richard D'Andrea, Binks Wattenberg
-
Publication number: 20070265196Abstract: The present invention relates generally to a method of modulating the proinflammatory activity of C-reactive protein in endothelial cells. More particularly, the present invention relates to down-regulation of proinflammatory activity of C-reactive protein in vascular endothelial cells. Accordingly, the method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of inflammatory conditions, particularly conditions characterised by proinflammatory activity of C-reactive protein in endothelial cells.Type: ApplicationFiled: January 21, 2005Publication date: November 15, 2007Applicant: MEDVET SCIENCE PTY., LTD.Inventors: Pu Xia, Carol Wadham, Mathew Vadas
-
Publication number: 20070071752Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.Type: ApplicationFiled: September 26, 2006Publication date: March 29, 2007Applicant: Johnson & Johnson Pharmaceutical R and D LLCInventors: Stuart Pitson, Brian Wattenberg, Pu Xia, Richard D'Andrea, Jennifer Gamble, Matthew Vadas
-
Patent number: 7172879Abstract: The invention relates to detection of sphingosine kinase activity and sphingosine kinase agonist or antagonist activity.Type: GrantFiled: October 7, 2003Date of Patent: February 6, 2007Assignee: Johnson & Johnson Pharmaceutical Research & Development LLPInventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Philip Barter, Kerry Anne Rye, Brian Wattenberg, Stuart Pitson
-
Patent number: 7112427Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.Type: GrantFiled: August 18, 2003Date of Patent: September 26, 2006Assignee: Johnson & Johnson Pharmaceutical Research and Development LLCInventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
-
Publication number: 20060205688Abstract: The present invention relates generally to a method of modulating endothelial cell functional characteristics and to agents useful for same. More particularly, the present invention relates to a method of modulating vascular endothelial cell pro-inflammatory and angiogenic phenotypes by modulating the functional levels of intracellular sphingosine kinase. The method of the present invention is useful, inter alia, in relation to the treatment and/or prophylaxis of conditions which are characterised by inadequate endothelial cell functioning and may include conditions such as vascular engraftment, organ transplantation or wound healing or conditions which are characterised by an aberrant endothelial cell inflammatory or angiogenic phenotype. Further, the method of the present invention facilitates the development of agents, such as functionally manipulated endothelial cell populations, for a range of therapeutic and/or prophylactic uses.Type: ApplicationFiled: October 14, 2003Publication date: September 14, 2006Applicant: Medvet Science Pty. Ltd.Inventors: Jennifer Gamble, Matthew Vadas, Stuart Pitson, Pu Xia, Vidya Limaye
-
Publication number: 20050100547Abstract: The present invention relates generally to a method of modulating cytokine-mediated cellular activity and to agents useful for same. More particularly, the present invention contemplates a method of modulating tumor necrosis factor-mediated cellular activity by modulating an intracellular sphingosine kinase-dependent signalling mechanism. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by aberrant, unwanted or otherwise inappropriate cytokine-mediated cellular activity The present invention is further directed to methods for identifying and/or designing agents capable of modulating the subject sphingosine kinase-dependent signalling mechanism.Type: ApplicationFiled: June 3, 2002Publication date: May 12, 2005Inventors: Pu Xia, Lijun Wang, Mathew Vadas, Jennifer Gamble, Paul Moretti, Stuart Pitson
-
Publication number: 20050074830Abstract: The present invention relates generally to a method of modulating cellular activity and agents useful for same. More particularly, the present invention contemplates a method of modulating endothelial cell activity and even more particularly endothelial cell adhesion molecule expression. Most particularly, the present invention provides a method of treating coronary heart disease by preventing or reducing endothelial cell adhesion molecule expression.Type: ApplicationFiled: October 7, 2003Publication date: April 7, 2005Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson
-
Publication number: 20050009732Abstract: A method of modulating the growth of a cell, such as a neoplastic or malignant cell from the colon, stomach, lung, brain, bone, esophagus, pancreas, breast, ovary or uterus includes contacting the cell with an agent for a time and under conditions sufficient to modulate the functional activity of sphingosine kinase in which down-regulation of the functional activity of the sphingosine kinase down-regulates growth of the cells and up-regulation of the functional activity of this sphingosine kinase up-regulates the growth of the cell. The down-regulation can reduce the functional activity of this sphingosine kinase to an oncogenic ineffective level.Type: ApplicationFiled: February 19, 2004Publication date: January 13, 2005Applicant: Medvet Science Pty Ltd.Inventors: Mathew Vadas, Jennifer Gamble, Pu Xia, Lijun Wang, Olga Sukocheva
-
Publication number: 20040132053Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic applications.Type: ApplicationFiled: August 18, 2003Publication date: July 8, 2004Applicant: Johnson & Johnson Pharmaceutical R and D LLCInventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
-
Patent number: 6730480Abstract: The present invention relates generally to novel protein molecules and to derivatives, analogues, chemical equivalents and mimetics thereof capable of modulating cellular activity and, in particular, modulating cellular activity via the modulation of signal transduction. More particularly, the present invention relates to human sphingosine kinase and to derivatives, analogues, chemical equivalents and mimetics thereof. The present invention also contemplates genetic sequences encoding said protein molecules and derivatives, analogues, chemical equivalents and mimetics thereof. The molecules of the present invention are useful in a range of therapeutic, prophylactic and diagnostic application.Type: GrantFiled: January 24, 2002Date of Patent: May 4, 2004Assignee: Johnson & Johnson Pharmaceutical Research and Development LLCInventors: Stuart Maxwell Pitson, Brian Wolff Wattenberg, Pu Xia, Richard James D'Andrea, Jennifer Ruth Gamble, Matthew Alexander Vadas
-
Publication number: 20040014635Abstract: The present invention relates generally to a method of modulating the growth of cells and, more particularly, to a method of down-regulating the growth of neoplastic cells. The present invention is useful, inter alia, in the therapeutic and/or prophylactic treatment of cancers such as, but not limited to, solid cancers such as cancers of the colon, stomach, lung, brain, bone, oesophagus, pancreas, breast, ovary or uterus.Type: ApplicationFiled: June 25, 2003Publication date: January 22, 2004Inventors: Mathew Vadas, Jennifer Gamble, Pu Xia, Lijen Wang
-
Patent number: 6649362Abstract: A screening method for identifying a therapeutic candidate for a coronary heart disease or an inflammatory condition is disclosed. The screening method tests for the presence or absence of an effect by a putative therapeutic agent on a component of a sphingosine kinase signaling pathway.Type: GrantFiled: October 16, 2001Date of Patent: November 18, 2003Assignee: Medvet Science Pty. Ltd.Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson
-
Publication number: 20020051777Abstract: The present invention relates generally to a method of modulating cellular activity and agents useful for same. More particularly, the present invention contemplates a method of modulating endothelial cell activity and even more particularly endothelial cell adhesion molecule expression. Most particularly, the present invention provides a method of treating coronary heart disease by preventing or reducing endothelial cell adhesion molecule expression.Type: ApplicationFiled: October 16, 2001Publication date: May 2, 2002Inventors: Jennifer Gamble, Mathew Vadas, Pu Xia, Phillip Barter, Kerry-Anne Rye, Brian Wattenberg, Stuart Pitson